Keywords: eisai, pravastatin, generic, sluggish, elmed, generics, subsidiary
Eisai's pravastatin generic sluggish
Article | 05 January 2004
Elmed Eisai, the generics subsidiary of Japanese drugmaker Eisai, has revised its fiscal 2003/4 sales forecast downward from 4 billion yen ($37.2 million) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
